StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners raised their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Trading Up 6.9 %

Shares of NASDAQ TNXP opened at $0.15 on Thursday. Tonix Pharmaceuticals has a 1-year low of $0.13 and a 1-year high of $24.16. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $0.33 and a two-hundred day moving average of $3.07. The company has a market cap of $3.21 million, a PE ratio of 0.00 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. As a group, equities analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,770,000 shares of the company’s stock after acquiring an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.